Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03839459 · OUTCOME

Proportion of Participants With Progression Free Survival at 3 Years

Denosumab for Smoldering Multiple Myeloma · Source last updated 2026-06-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
3 years

What was measured

Progression free survival was defined as the absence of disease progression or death from any cause at the 3 year assessment time point.

Analysis population: The analysis includes participants with available progression free survival follow up data at the 3 year assessment time point.

Groups in this outcome

Denosumab

Denosumab: 120mg of Denosumab will be administered subcutaneously once every 4 weeks

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Denosumab8

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Denosumab8Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        8
denoms
  1. counts
    1. group Id
      OG000
      value
      8
    units
    Participants
description
Progression free survival was defined as the absence of disease progression or death from any cause at the 3 year assessment time point.
groups
  1. description
    Denosumab: 120mg of Denosumab will be administered subcutaneously once every 4 weeks
    id
    OG000
    title
    Denosumab
param Type
NUMBER
population Description
The analysis includes participants with available progression free survival follow up data at the 3 year assessment time point.
reporting Status
POSTED
time Frame
3 years
title
Proportion of Participants With Progression Free Survival at 3 Years
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice